Long-form research.
Mechanism · administration · safety.

BPC-157 and TB-500 are the most widely self-researched peptides in the recovery and healing space. BPC-157 was originally derived from a protein found in gastric juice and has shown remarkable tissue-repair properties in animal models — from torn tendons to gut ulcers to nerve injuries. TB-500 is a synthetic fragment of Thymosin Beta-4, a protein present in virtually every cell of the body that plays a central role in tissue repair and new blood vessel formation. Together they represent two distinct but complementary approaches to accelerating the body's natural healing processes. Both are available from EU-based research vendors and are among the most studied peptides in the self-research community.

Muscle growth peptide research focuses on compounds that stimulate the body's own muscle-building pathways — particularly the IGF-1/mTOR signalling axis and satellite cell activation. IGF-1 LR3 is a long-acting form of Insulin-like Growth Factor 1, a hormone naturally produced in the liver that drives muscle protein synthesis and satellite cell (muscle stem cell) proliferation. TB-500, also studied in the healing category, contributes here through its role in directing satellite cells to repair sites and improving blood supply to muscle tissue. These peptides are studied by researchers interested in skeletal muscle biology, hypertrophy mechanisms, and post-injury muscle recovery.

Semax and Selank are Soviet-era synthetic peptides developed in Russia during the 1970s–80s and still prescribed there today for stroke recovery, anxiety disorders, and cognitive decline. Unlike stimulants (which flood the brain with dopamine) or sedatives (which suppress neuronal activity), these peptides work by upregulating the brain's own growth and repair factors. Semax stimulates the production of BDNF — brain-derived neurotrophic factor — a protein critical for learning, memory, and neuronal survival. Selank modulates the GABA system, the brain's primary calming pathway, producing anxiolytic effects without the sedation or dependence risk of benzodiazepines. A key practical advantage: both are administered as nasal sprays, bypassing the need for injections.

Epithalon and GHK-Cu sit at the frontier of longevity science. Epithalon is a synthetic tetrapeptide developed by Russian gerontologist Vladimir Khavinson from pineal gland extracts. It is one of the very few compounds shown in peer-reviewed studies to activate telomerase — the enzyme responsible for repairing the ends of chromosomes — in human cell cultures. Longer telomeres are associated with slower cellular ageing and reduced age-related disease risk. GHK-Cu is a naturally occurring copper-peptide complex found in human plasma, saliva, and urine. Its concentration drops dramatically with age — from ~200 ng/mL at age 20 to under 80 ng/mL by age 60 — and it regulates an extraordinary number of biological processes including collagen production, antioxidant defence, anti-inflammatory signalling, and stem cell activation. Both peptides attract significant interest from the longevity research and biohacker communities.

Thymosin Alpha-1 stands apart from most research peptides by having the most robust clinical validation: it is an approved pharmaceutical (Zadaxin®) in over 35 countries including Italy, China, and various Asian and Eastern European nations. The thymus gland produces Thymosin Alpha-1 naturally to "educate" T-cells — white blood cells that coordinate the immune response. As we age, thymic output declines, and with it the efficiency of our immune surveillance. Thymosin Alpha-1 is studied to restore this immune competence: activating natural killer cells, boosting T-cell populations, and enhancing the body's response to vaccines and infections. It is of particular interest to self-researchers focused on immune optimisation, post-illness recovery, and age-related immune decline.

Weight loss peptide research centres on compounds that either directly break down fat cells or stimulate the body's own growth hormone — which drives fat burning, lean mass preservation, and metabolic health. AOD-9604 is an engineered fragment of human growth hormone designed specifically to activate fat-cell breakdown (lipolysis) without the blood sugar dysregulation or anabolic side-effects of full-length HGH. CJC-1295 and Ipamorelin are studied in combination: CJC-1295 signals the pituitary gland to produce more growth hormone, while Ipamorelin amplifies the resulting pulse — producing up to 5× more GH than either compound alone, with a highly selective profile that avoids the cortisol and prolactin increases seen with older GH-releasing peptides. Together, these compounds represent a sophisticated approach to metabolic research that goes well beyond simple calorie restriction.

Sleep quality is increasingly recognised as one of the most powerful levers for health, cognitive performance, and longevity. DSIP (Delta Sleep-Inducing Peptide) was discovered in 1977 when researchers isolated it from rabbit blood during natural sleep and found that injecting it into alert rabbits induced slow-wave (deep) sleep within 30 minutes. Unlike sleeping pills, which work by broadly suppressing brain activity, DSIP specifically promotes delta-wave (slow-wave) sleep — the deepest and most restorative stage — without sedation, respiratory depression, or dependence. Selank contributes to this category through its anxiolytic mechanism: by reducing the hyperarousal (racing thoughts, elevated cortisol, difficulty switching off) that underlies stress-induced insomnia, without the muscle-relaxing or respiratory effects of benzodiazepines.

PT-141, known clinically as Bremelanotide and sold as Vyleesi®, is the only FDA-approved peptide specifically for sexual dysfunction — approved in 2019 for hypoactive sexual desire disorder in premenopausal women. What makes PT-141 unique is where it acts: not in the blood vessels, like Viagra or Cialis, but in the brain. It activates melanocortin receptors in the hypothalamus — a region involved in desire, arousal, and motivation — producing an increase in sexual interest that is centrally driven rather than mechanically facilitated. This makes it relevant for addressing the desire and psychological components of sexual dysfunction, which PDE5 inhibitors cannot reach. It has been studied in both men and women, giving it one of the broadest clinical research bases of any peptide on this site.